SG161208A1 - Therapeutic compositions for intranasal administration of ketorolac - Google Patents

Therapeutic compositions for intranasal administration of ketorolac

Info

Publication number
SG161208A1
SG161208A1 SG201001999-0A SG2010019990A SG161208A1 SG 161208 A1 SG161208 A1 SG 161208A1 SG 2010019990 A SG2010019990 A SG 2010019990A SG 161208 A1 SG161208 A1 SG 161208A1
Authority
SG
Singapore
Prior art keywords
compositions
ketorolac
therapeutic compositions
intranasal administration
nasally administered
Prior art date
Application number
SG201001999-0A
Other languages
English (en)
Inventor
Roger Whiting
Ramachandran Thirucote
Original Assignee
Roxro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roxro Pharma Inc filed Critical Roxro Pharma Inc
Publication of SG161208A1 publication Critical patent/SG161208A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201001999-0A 2004-12-23 2005-12-15 Therapeutic compositions for intranasal administration of ketorolac SG161208A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63902204P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
SG161208A1 true SG161208A1 (en) 2010-05-27

Family

ID=36390269

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001999-0A SG161208A1 (en) 2004-12-23 2005-12-15 Therapeutic compositions for intranasal administration of ketorolac

Country Status (16)

Country Link
US (1) US20090042968A1 (de)
EP (1) EP1835911B1 (de)
JP (2) JP4966204B2 (de)
KR (1) KR20070091682A (de)
CN (1) CN101083984B (de)
AR (1) AR052347A1 (de)
AU (1) AU2005322305B2 (de)
CA (1) CA2587792C (de)
CR (1) CR9261A (de)
IL (1) IL183256A (de)
MX (1) MX2007007504A (de)
NO (1) NO20073774L (de)
NZ (1) NZ555247A (de)
SG (1) SG161208A1 (de)
WO (1) WO2006071601A2 (de)
ZA (2) ZA200704869B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
AU2005322305B2 (en) * 2004-12-23 2010-09-16 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
TW201002368A (en) * 2008-06-13 2010-01-16 Roxro Pharma Inc Unit dose formulations of ketorolac for intranasal administration
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
CN102614122B (zh) * 2011-01-28 2013-10-16 上海现代药物制剂工程研究中心有限公司 酮咯酸氨丁三醇鼻腔喷雾剂及其制备方法
WO2012127497A1 (en) 2011-03-04 2012-09-27 Cadila Healthcare Limited Stable pharmaceutical compositions of ketorolac or salts thereof
SG194927A1 (en) * 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
CN114191417A (zh) * 2021-12-17 2022-03-18 上海清芮科技有限公司 一种用于宠物的雾化吸入剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
JPH07112984B2 (ja) * 1989-04-28 1995-12-06 久光製薬株式会社 泡状エアゾール製剤
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
AU2005322305B2 (en) * 2004-12-23 2010-09-16 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac

Also Published As

Publication number Publication date
MX2007007504A (es) 2007-09-14
IL183256A0 (en) 2007-10-31
ZA200806671B (en) 2009-04-29
EP1835911A2 (de) 2007-09-26
NZ555247A (en) 2010-06-25
JP2009001586A (ja) 2009-01-08
CA2587792C (en) 2010-07-06
CN101083984B (zh) 2010-11-10
AR052347A1 (es) 2007-03-14
CR9261A (es) 2008-03-18
CA2587792A1 (en) 2006-07-06
ZA200704869B (en) 2009-02-25
CN101083984A (zh) 2007-12-05
AU2005322305B2 (en) 2010-09-16
WO2006071601A2 (en) 2006-07-06
JP4966204B2 (ja) 2012-07-04
NO20073774L (no) 2007-09-05
KR20070091682A (ko) 2007-09-11
IL183256A (en) 2011-02-28
US20090042968A1 (en) 2009-02-12
AU2005322305A1 (en) 2006-07-06
EP1835911B1 (de) 2012-08-29
WO2006071601A3 (en) 2006-08-17
JP2008525455A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
SG161208A1 (en) Therapeutic compositions for intranasal administration of ketorolac
TW200603787A (en) Topical preparations containing ambroxol
HK1176318A1 (en) Injection device
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2005123192A3 (en) Improving pain treatment with strontium combinations
CA2632207C (en) Use of calcitonin for the treatment of ra
MX2009011900A (es) Curacion de herida diabetica.
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX2011008132A (es) Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis.
WO2006063164A3 (en) Compositions and methods for treating neuroendocrine tumors
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia